Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including CTLA-4 and PD-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies (mAb) have demonstrated survival benefits in numerous cancers, including melanoma and non-small... View More